A 16-year-old diabetic patient developed Rhizopus pneumonia and was initially treated with amphotericin B for 7 days. Because of clinical deterioration of the patient, rifampin was added empirically. The 
Invasive infections caused by Rhizopus spp. occur primarily in patients with underlying diseases such as leukemia, lymphoma, and diabetes mellitus and are associated with high morbidity and mortality (14) . Successful management of these patients depends on how early the diagnosis is made, prolonged antifungal therapy, and aggressive surgical debridement. Various rates of survival have been reported (13) . Amphotericin B is the drug of choice for these infections; however, the prolonged therapy with high dosage that is usually required may be associated with severe toxicity (13) .
On the basis of previous reports (1, 3, 4, (8) (9) (10) of in vitro synergy between amphotericin B and rifampin against various fungi, we used this combination to treat a 16-year-old diabetic patient with Rhizopus pneumonia. Further study was undertaken to analyze the in vitro activity of amphotericin B alone and in combination with rifampin against the isolate from this patient and 11 additional isolates of Rhizopus spp.
CASE REPORT
A 16-year-old female in diabetic ketoacidosis was hospitalized on 16 By the definition of synergism given above, three of six isolates tested by dose-response curves were synergistically inhibited by amphotericin B-rifampin (Fig. 1) . Synergism is demonstrated in R. oryzae isolates 1, 8, and 7 (Fig. 1A, B , and C, respectively). Two other isolates showed synergism, but only at certain amphotericin B concentrations, i. e., one at 0.031 ,ug/ml (Fig. 1D, R. arrhyzus) and the other at 0.015 ,g/ml (Fig. 1E, R . oryzae isolate 4). This was observed at rifampin concentrations of 5 and 10 ,ug/ml.
The only environmental isolate (R. nigricans) tested demonstrated a dose-response curve suggestive of possible antagonism (Fig. 1F, isolate 11 ). Not depicted in the figure are the results of rifampin alone at various concentrations, which showed no antifungal activity.
The effect of the two compounds and their various combinations on the dose-response curves of germinated spores of isolates 7 and 8 is demonstrated in Fig. 1G Cryptococcus neoformans (15) , and Aspergillus spp. (10, 11) . In each study, including ours, rifampin alone had no effect on the fungal strains, whereas the addition of amphotericin B resulted in apparent synergy at clinically achievable drug concentrations. Medoff et al. (16) successfully treated with the amphotericin B-rifampin combination (5, 7, 17) . However, to date, no prospective comparative studies of the combination in invasive fungal infection of humans have been reported.
In vivo therapeutic studies of invasive Rhizopus infection are needed to extend our observations of synergy. Comparative clinical studies, however, are difficult to conduct, since infections caused by Rhizopus spp. and other fungi belonging to the order Mucorales are uncommon. Therefore, the use of patients as their own controls, by measuring the fungistatic activity of serum against their own isolates before and after rifampin is added to amphotericin B, may provide an indication of in vivo synergy in an individual patient. This may lead to an improved clinical outcome and possibly allow use of lower, less-toxic doses of amphotericin B.
It is possible that other members of the order Mucorales will demonstrate results similar to those observed with Rhizopus spp., but further studies are warranted.
